AstraZeneca placed on ‘Positive Catalyst Watch’ at JPMorgan

JPMorgan placed AstraZeneca on “Positive Catalyst Watch” ahead of the company’s Q1 results on April 25. The analyst expects sequential sales acceleration of seven percentage points and sequential core EBIT margin expansion of 11 points, reassuring the market post the concerns coming out of Q4. The firm also expects peak sales guidance for AstraZeneca’s key pipeline assets to drive a “very strong” growth outlook. It keeps an Overweight rating on the shares with a GBp 13,000 price target.